The role of FOXD2-AS1 in cancer: a comprehensive study based on data mining and published articles

Zhang, Yongping; Liang, Chaojie; Wang, Zhinmin; Li, Ruihuan; Wei, Zhigang; Guo, Jiansheng

doi:10.1042/bsr20190372

Cited by 6 publications

(6 citation statements)

References 48 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Moreover, MINCR is also overexpressed in hepatocellular carcinoma and gall bladder cancer, and its overexpression promotes cell proliferation, migration, and invasion [ 37 , 38 ]. The lncRNA FOXD2-AS1 is abnormally expressed in a number of cancers and affects tumor progression [ 39 ]. Ni et al revealed that FoxD2-AS1 regulates the miR-185-5P/HMGA2 axis and the PI3K/AKT signaling pathway to promote glioma progression [ 40 ].…”

Section: Discussionmentioning

confidence: 99%

Construction and Validation of a Novel Cuproptosis-Related Seven-lncRNA Signature to Predict the Outcomes, Immunotherapeutic Responses, and Targeted Therapy in Patients with Clear Cell Renal Cell Carcinoma

et al. 2023

View full text Add to dashboard Cite

Background. Cuproptosis was recently recognized as a novel form of cell death, linked closely to the occurrence and progression of cancer. We aimed to identify prognostic cuproptosis-related long noncoding RNAs (lncRNAs) and build a risk signature to predict the prognosis and treatment responses of clear cell renal cell carcinoma (ccRCC) in this work. Methods. LASSO–Cox regression was conducted to construct the signature based on prognostic cuproptosis-related lncRNAs (CR-lncRNAs). The signature’s reliability and sensitivity were assessed by the Kaplan-Meier survival analysis and receiver operating characteristic analysis. External validation was performed via data from the International Cancer Genome Consortium database. On the basis of CR-lncRNAs, an lncRNA-microRNA-mRNA regulatory network was created, and functional enrichment analysis was used to investigate the underlying biological roles of these genes. In addition, the relationship between the risk signature and immunotherapy and targeted therapy responses was examined. Finally, the expression levels of seven candidate lncRNAs between tumor and normal cells were compared in vitro using quantitative real-time PCR. Results. A seven-CR-lncRNA risk signature was constructed, which showed a stronger potential for survival prediction than standard clinicopathological features in patients with kidney cancer. Functional enrichment analysis showed that the CR-lncRNA risk signature was enriched in ion transport-related molecular functions as well as various immune-related biological processes. Furthermore, we discovered that individuals in the high-risk group were more likely than those in the low-risk group to respond to immunotherapy and targeted therapies with medications like sunitinib and pazopanib. Finally, quantitative real-time PCR revealed that the expression levels of seven candidate lncRNAs differed significantly between RCC and healthy kidney cells. Conclusion. In summary, we generated a CR-lncRNA risk signature that may be utilized to predict outcomes in patients with ccRCC and responsiveness to immunotherapy and targeted treatment, potentially serving as a reference for clinical personalized medicine.

show abstract

Section: Discussionmentioning

confidence: 99%

Construction and Validation of a Novel Cuproptosis-Related Seven-lncRNA Signature to Predict the Outcomes, Immunotherapeutic Responses, and Targeted Therapy in Patients with Clear Cell Renal Cell Carcinoma

et al. 2023

View full text Add to dashboard Cite

show abstract

“…LINC00460 was usually upregulated in cervical cancer tissues and cell lines, knockdown of LINC00460 restrain cervical cancer cell growth and invasion in vitro and attenuated tumorigenesis in vivo [ 17 ]. Overexpressed FOXD2-AS1 is linked to tumor size and TNM stage and a risk factor of OS and disease-free survival (DFS) in cancer patients [ 18 ]. EMX2OS is a key metabolism-related enhancer RNA in KIRC with a favorable impact on survival [ 19 ] and EMX2OS is regulated by TCF12 transcription and co-regulates the proliferation, migration and invasion of prostate cancer cells with FUS protein by activating cGMP-PKG pathway [ 20 ].…”

Section: Discussionmentioning

confidence: 99%

An epithelial-mesenchymal transition-related long non-coding RNA signature to predict overall survival and immune microenvironment in kidney renal clear cell carcinoma

Zhang

Cheng

et al. 2021

Bioengineered

View full text Add to dashboard Cite

show abstract

“…Overall, almost all oncogene lncRNAs regulate the cell cycle, promote tumor proliferation, inhibit apoptosis, and induce tumor invasiveness and migration. While lncRNAs such as XIST (162-172), CRDNE (173-179), FOXD2-AS1 (186)(187)(188)(189)(190)(191)(192)(193)(194), ANRIL (195)(196)(197), HOXA11-AS (198)(199)(200)(201)(202)(203), TP73-AS1 (204)(205)(206), and DANCR (207-210) are only known as tumor inducers, the ultimate function of some lncRNAs is controversial. For instance, for MALAT1, NEAT1, and TUG1, both oncogenic and tumor suppressor effects have been reported.…”

Section: Role In Tumor Pathologymentioning

confidence: 99%

“…Prognostic value: Higher expression of NEAT1 (147), XIST (164), CRNDE (173, 179), FOXD2-AS1 (186,189,192,194), ANRIL (196), HOXA11-AS (198)(199)(200)203), TP73-AS1 (204,242),…”

Section: Clinical Applicationsmentioning

confidence: 99%

“…Prognostic value : Higher expression of NEAT1 ( 147 ), XIST ( 164 ), CRNDE ( 173 , 179 ), FOXD2-AS1 ( 186 , 189 , 192 , 194 ), ANRIL ( 196 ), HOXA11-AS ( 198 – 200 , 203 ), TP73-AS1 ( 204 , 242 ), and DANCR ( 208 , 210 , 243 ), in addition to lower expression of GAS5 ( 220 ), CASC2 ( 222 , 244 ), TUSC7 ( 240 ) correlated with a more advanced stage of disease or poor survival ( Figure 3 ). Notably, controversial findings were reported for some lncRNAs.…”

Section: Lncrnas In Gliomamentioning

confidence: 99%

See 1 more Smart Citation

Long Non-Coding RNAs in Diagnosis, Treatment, Prognosis, and Progression of Glioma: A State-of-the-Art Review

Momtazmanesh

Rezaei

2021

Front. Oncol.

View full text Add to dashboard Cite

Glioma is the most common malignant central nervous system tumor with significant mortality and morbidity. Despite considerable advances, the exact molecular pathways involved in tumor progression are not fully elucidated, and patients commonly face a poor prognosis. Long non-coding RNAs (lncRNAs) have recently drawn extra attention for their potential roles in different types of cancer as well as non-malignant diseases. More than 200 lncRNAs have been reported to be associated with glioma. We aimed to assess the roles of the most investigated lncRNAs in different stages of tumor progression and the mediating molecular pathways in addition to their clinical applications. lncRNAs are involved in different stages of tumor formation, invasion, and progression, including regulating the cell cycle, apoptosis, autophagy, epithelial-to-mesenchymal transition, tumor stemness, angiogenesis, the integrity of the blood-tumor-brain barrier, tumor metabolism, and immunological responses. The well-known oncogenic lncRNAs, which are upregulated in glioma, are H19, HOTAIR, PVT1, UCA1, XIST, CRNDE, FOXD2-AS1, ANRIL, HOXA11-AS, TP73-AS1, and DANCR. On the other hand, MEG3, GAS5, CCASC2, and TUSC7 are tumor suppressor lncRNAs, which are downregulated. While most studies reported oncogenic effects for MALAT1, TUG1, and NEAT1, there are some controversies regarding these lncRNAs. Expression levels of lncRNAs can be associated with tumor grade, survival, treatment response (chemotherapy drugs or radiotherapy), and overall prognosis. Moreover, circulatory levels of lncRNAs, such as MALAT1, H19, HOTAIR, NEAT1, TUG1, GAS5, LINK-A, and TUSC7, can provide non-invasive diagnostic and prognostic tools. Modulation of expression of lncRNAs using antisense oligonucleotides can lead to novel therapeutics. Notably, a profound understanding of the underlying molecular pathways involved in the function of lncRNAs is required to develop novel therapeutic targets. More investigations with large sample sizes and increased focus on in-vivo models are required to expand our understanding of the potential roles and application of lncRNAs in glioma.

show abstract

The role of FOXD2-AS1 in cancer: a comprehensive study based on data mining and published articles

Cited by 6 publications

References 48 publications

Construction and Validation of a Novel Cuproptosis-Related Seven-lncRNA Signature to Predict the Outcomes, Immunotherapeutic Responses, and Targeted Therapy in Patients with Clear Cell Renal Cell Carcinoma

Construction and Validation of a Novel Cuproptosis-Related Seven-lncRNA Signature to Predict the Outcomes, Immunotherapeutic Responses, and Targeted Therapy in Patients with Clear Cell Renal Cell Carcinoma

An epithelial-mesenchymal transition-related long non-coding RNA signature to predict overall survival and immune microenvironment in kidney renal clear cell carcinoma

Long Non-Coding RNAs in Diagnosis, Treatment, Prognosis, and Progression of Glioma: A State-of-the-Art Review

Contact Info

Product

Resources

About